Key result
Fibroblast-specific FMO2 restoration reduces post-MI cardiac fibrosis and improves LV function across preclinical models.
Why the study?
Cardiac fibrosis lacks effective therapy and the functional role of FMO2 in post-MI cardiac remodeling was largely unknown.
Does fibroblast-specific restoration of FMO2 expression attenuate cardiac fibrosis and improve ventricular function following myocardial infarction in preclinical rodent and non-human primate models?
Does fibroblast-specific restoration of FMO2 expression attenuate cardiac fibrosis and improve ventricular function following myocardial infarction in preclinical rodent and non-human primate models?
Answers are grounded in this paper and cite their sources.
This study identifies FMO2 as a conserved, enzyme-independent endogenous inhibitor of TGF-beta/SMAD2/3 signaling in cardiac fibroblasts via the CYP2J3-SMURF2 axis, demonstrating in both rodents and non-human primates that FMO2 gene transfer is a promising therapeutic strategy to prevent post-MI cardiac fibrosis and heart failure.
Background: Cardiac fibrosis is a common pathological feature associated with adverse clinical outcome in postinjury remodeling and has no effective therapy. Using an unbiased transcriptome analysis, we identified FMO2 (flavin-containing monooxygenase 2) as a top-ranked gene dynamically expressed following myocardial infarction (MI) in hearts across different species including rodents, nonhuman primates, and human. However, the functional role of FMO2 in cardiac remodeling is largely unknown. Methods: Single-nuclei transcriptome analysis was performed to identify FMO2 after MI; FMO2 ablation rats were generated both in genetic level using the CRISPR-cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat–associated 9) technology and lentivirus-mediated manner. Gain-of-function experiments were conducted using postn -promoter FMO2, miR1a/miR133a-FMO2 lentivirus, and enzymatic activity mutant FMO2 lentivirus after MI. Results: A significant downregulation of FMO2 was consistently observed in hearts after MI in rodents, nonhuman primates, and patients. Single-nuclei transcriptome analysis showed cardiac expression of FMO2 was enriched in fibroblasts rather than myocytes. Elevated spontaneous tissue fibrosis was observed in the FMO2-null animals without external stress. In contrast, fibroblast-specific expression of FMO2 markedly reduced cardiac fibrosis following MI in rodents and nonhuman primates associated with diminished SMAD2/3 (small mothers against decapentaplegic 2/3) phosphorylation. Unexpectedly, the FMO2-mediated regulation in fibrosis and SMAD2/3 signaling was independent of its enzymatic activity. Rather, FMO2 was detected to interact with CYP2J3 (cytochrome p450 superfamily 2J3). Binding of FMO2 to CYP2J3 disrupted CYP2J3 interaction with SMURF2 (SMAD-specific E3 ubiquitin ligase 2) in cytosol, leading to increased cytoplasm to nuclear translocation of SMURF2 and consequent inhibition of SMAD2/3 signaling. Conclusions: Loss of FMO2 is a conserved molecular signature in postinjury hearts. FMO2 possesses a previously uncharacterized enzyme-independent antifibrosis activity via the CYP2J3-SMURF2 axis. Restoring FMO2 expression exerts potent ameliorative effect against fibrotic remodeling in postinjury hearts from rodents to nonhuman primates. Therefore, FMO2 is a potential therapeutic target for treating cardiac fibrosis following injury.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2022) studied Cardiac fibrosis and pathological remodeling post-myocardial infarction. Fibroblast-specific FMO2 gene transfer (via lentiviral vectors LV-FMO2, LV-nmFMO2, Postn-promoter FMO2, and LV-MnmFMO2) vs. Control lentiviral vector or sham/untreated post-MI controls was evaluated on Cardiac fibrosis (scar size, interstitial fibrosis, collagen deposition) and cardiac function (ejection fraction and chamber dilation via echocardiography and CMR). Fibroblast-specific FMO2 restoration significantly reduced cardiac fibrosis and improved left ventricular systolic function after myocardial infarction in rodents and non-human primates via the CYP2J3-SMURF2 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: